Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Implementation of Pre-emptive Geno- and Phenotyping in 5-Fluorouracil- or Capecitabine-treated Patients With the Aim of Reducing Toxicity

NCT04269369 is registered in ClinicalTrials.gov with Jessa Hospital as lead sponsor.

NCT NCT04269369
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04269369 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Implementation of Pre-emptive Geno- and Phenotyping in 5-Fluorouracil- or Capecitabine-treated Patients With the Aim of Reducing Toxicity
Lead sponsor
Jessa Hospital
Phase
Phase 4
Overall status
Unknown status
Start date
February 18, 2020
Completion date
September 30, 2021
Enrollment
250 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

anal tumor, colon cancer, esophageal cancer, pancreas cancer, stomach tumor